{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T21:19:09Z","timestamp":1785014349636,"version":"3.55.0"},"reference-count":74,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental and Molecular Pathology"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.yexmp.2024.104898","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T20:32:42Z","timestamp":1715286762000},"page":"104898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Fate control engagement augments NK cell responses in LV\/hu-IL-12 transduced sarcoma"],"prefix":"10.1016","volume":"137","author":[{"given":"Mary Jo","family":"Rademacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary L.","family":"Faber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Bone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A.","family":"Medin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan J.","family":"Schloemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.yexmp.2024.104898_bb0005","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.3389\/fimmu.2018.01869","article-title":"Natural killer cells: development, maturation, and clinical utilization","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.yexmp.2024.104898_bb0010","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.3389\/fimmu.2018.01168","article-title":"IQ domain-containing GTPase-activating protein 1 regulates cytoskeletal reorganization and facilitates NKG2D-mediated mechanistic target of rapamycin complex 1 activation and cytokine gene translation in natural killer cells","volume":"9","author":"Abel","year":"2018","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.yexmp.2024.104898_bb0015","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/jso.21140","article-title":"High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions","volume":"98","author":"Bacci","year":"2008","journal-title":"J. Surg. Oncol."},{"issue":"1","key":"10.1016\/j.yexmp.2024.104898_bb0020","doi-asserted-by":"crossref","first-page":"3234","DOI":"10.1038\/s41598-022-07281-6","article-title":"The metabolism of cells regulates their sensitivity to NK cells depending on p53 status","volume":"12","author":"Belkahla","year":"2022","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.yexmp.2024.104898_bb0025","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/2045-3329-2-8","article-title":"Histone deacetylase inhibitors enhance expression of NKG2D ligands in Ewing sarcoma and sensitize for natural killer cell-mediated cytolysis","volume":"2","author":"Berghuis","year":"2012","journal-title":"Clin. Sarcoma Res."},{"issue":"23","key":"10.1016\/j.yexmp.2024.104898_bb0030","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1002\/cncr.27651","article-title":"Long-term results (>25 years) of a randomized, prospective clinical trial evaluating chemotherapy in patients with high-grade, operable osteosarcoma","volume":"118","author":"Bernthal","year":"2012","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.yexmp.2024.104898_bb0035","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1097\/00000658-199905000-00002","article-title":"Pulmonary metastases from soft tissue sarcoma","volume":"229","author":"Billingsley","year":"1999","journal-title":"Ann. Surg."},{"issue":"11","key":"10.1016\/j.yexmp.2024.104898_bb0040","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0192-0561(96)00064-1","article-title":"Antiviral activity of biological response modifiers in a murine model of aids. Requirement for augmentation of natural killer cell activity and synergy with oral AZT","volume":"18","author":"Black","year":"1996","journal-title":"Int. J. Immunopharmacol."},{"issue":"5","key":"10.1016\/j.yexmp.2024.104898_bb0045","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/cdli.1.5.538-544.1994","article-title":"Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS","volume":"1","author":"Brenner","year":"1994","journal-title":"Clin. Diagn. Lab. Immunol."},{"issue":"10","key":"10.1016\/j.yexmp.2024.104898_bb0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0301-472X(03)00226-1","article-title":"Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions","volume":"31","author":"Burt","year":"2003","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.yexmp.2024.104898_bb0055","doi-asserted-by":"crossref","first-page":"601","DOI":"10.3389\/fimmu.2015.00601","article-title":"Natural killer cell immunomodulation: targeting activating, inhibitory, and co-stimulatory receptor signaling for Cancer immunotherapy","volume":"6","author":"Chester","year":"2015","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.yexmp.2024.104898_bb0060","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1186\/1471-2407-14-957","article-title":"MICA\/B and ULBP1 NKG2D ligands are independent predictors of good prognosis in cervical cancer","volume":"14","author":"Cho","year":"2014","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.yexmp.2024.104898_bb0065","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(09)70074-9","article-title":"Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study","volume":"10","author":"Ciceri","year":"2009","journal-title":"Lancet Oncol."},{"issue":"2","key":"10.1016\/j.yexmp.2024.104898_bb0070","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1074-7613(01)00095-4","article-title":"ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor","volume":"14","author":"Cosman","year":"2001","journal-title":"Immunity"},{"issue":"3","key":"10.1016\/j.yexmp.2024.104898_bb0075","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/hep.510290353","article-title":"Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver","volume":"29","author":"de la Asunci\u00f3n","year":"1999","journal-title":"Hepatology"},{"issue":"16","key":"10.1016\/j.yexmp.2024.104898_bb0080","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1158\/1078-0432.CCR-07-0776","article-title":"Interleukin-12: biological properties and clinical application","volume":"13","author":"Del Vecchio","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"18","key":"10.1016\/j.yexmp.2024.104898_bb0085","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.yexmp.2024.104898_bb0090","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1323161","article-title":"Tumor-targeted IL-12 combined with local irradiation leads to systemic tumor control via abscopal effects in vivo","volume":"6","author":"Eckert","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.yexmp.2024.104898_bb0095","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.975233","article-title":"Combinatorial suicide gene strategies for the safety of cell therapies","volume":"13","author":"Falcon","year":"2022","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.yexmp.2024.104898_bb0100","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1097\/00042560-199606010-00010","article-title":"Inhibition of murine AIDS by combination of AZT and dideoxycytidine 5\u2032-triphosphate","volume":"12","author":"Fraternale","year":"1996","journal-title":"J. Acquir. Immune Defic. Syndr. Hum. Retrovirol."},{"key":"10.1016\/j.yexmp.2024.104898_bb0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front. Pharmacol."},{"issue":"9","key":"10.1016\/j.yexmp.2024.104898_bb0110","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/bjc.2017.79","article-title":"MHC class I chain-related protein a and B (MICA and MICB) are predominantly expressed intracellularly in tumour and normal tissue","volume":"116","author":"Ghadially","year":"2017","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.yexmp.2024.104898_bb0115","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/jnci\/51.5.1417","article-title":"In vitro cultivation of human tumors: establishment of cell lines derived from a series of solid tumors","volume":"51","author":"Giard","year":"1973","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.yexmp.2024.104898_bb0120","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.08474","article-title":"A forward genetic screen reveals novel independent regulators of ULBP1, an activating ligand for natural killer cells","volume":"4","author":"Gowen","year":"2015","journal-title":"Elife"},{"issue":"8","key":"10.1016\/j.yexmp.2024.104898_bb0125","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa020890","article-title":"Addition of Ifosfamide and etoposide to standard chemotherapy for Ewing\u2019s sarcoma and primitive Neuroectodermal tumor of bone","volume":"348","author":"Grier","year":"2003","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.yexmp.2024.104898_bb0130","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.3324\/haematol.2008.001677","article-title":"Retroviral transfer of human CD20 as a suicide gene for adoptive T-cell therapy","volume":"94","author":"Griffioen","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.yexmp.2024.104898_bb0135","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.755639","article-title":"Inclusion of the inducible caspase 9 suicide gene in CAR construct increases safety of CAR.CD19 T cell therapy in B-cell malignancies","volume":"12","author":"Guercio","year":"2021","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.yexmp.2024.104898_bb0140","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","article-title":"NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy","volume":"28","author":"Guerra","year":"2008","journal-title":"Immunity"},{"issue":"11","key":"10.1016\/j.yexmp.2024.104898_bb0145","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1200\/JCO.1998.16.11.3641","article-title":"Treatment of metastatic osteosarcoma at diagnosis: a pediatric oncology group study","volume":"16","author":"Harris","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.yexmp.2024.104898_bb0150","doi-asserted-by":"crossref","first-page":"16074","DOI":"10.1038\/mtm.2016.74","article-title":"Preclinical validation: LV\/IL-12 transduction of patient leukemia cells for immunotherapy of AML","volume":"3","author":"Huang","year":"2016","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"20","key":"10.1016\/j.yexmp.2024.104898_bb0155","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.18632\/oncotarget.27546","article-title":"Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway","volume":"11","author":"Idso","year":"2020","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.yexmp.2024.104898_bb0160","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/10430340050015798","article-title":"Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies","volume":"11","author":"Introna","year":"2000","journal-title":"Hum. Gene Ther."},{"issue":"27","key":"10.1016\/j.yexmp.2024.104898_bb0165","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1200\/JCO.2014.59.4895","article-title":"Osteosarcoma: current treatment and a collaborative pathway to success","volume":"33","author":"Isakoff","year":"2015","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.yexmp.2024.104898_bb0170","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jhep.2011.06.017","article-title":"Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence","volume":"56","author":"Kamimura","year":"2012","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.yexmp.2024.104898_bb0175","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1089\/hum.2018.180","article-title":"A cetuximab-mediated suicide system in chimeric antigen receptor\u2013modified hematopoietic stem cells for cancer therapy","volume":"30","author":"Kao","year":"2019","journal-title":"Hum. Gene Ther."},{"issue":"5","key":"10.1016\/j.yexmp.2024.104898_bb0180","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1002\/1521-4141(200105)31:5<1428::AID-IMMU1428>3.0.CO;2-4","article-title":"ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells","volume":"31","author":"Kubin","year":"2001","journal-title":"Eur. J. Immunol."},{"issue":"8B","key":"10.1016\/j.yexmp.2024.104898_bb0185","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1111\/j.1582-4934.2008.00412.x","article-title":"IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy","volume":"13","author":"Labbe","year":"2009","journal-title":"J. Cell. Mol. Med."},{"issue":"8","key":"10.1016\/j.yexmp.2024.104898_bb0190","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.3390\/v13081528","article-title":"Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives","volume":"13","author":"Labb\u00e9","year":"2021","journal-title":"Viruses"},{"issue":"1\u20132","key":"10.1016\/j.yexmp.2024.104898_bb0195","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1615\/CritRevOncog.2014011142","article-title":"NK cells in the tumor microenvironment","volume":"19","author":"Larsen","year":"2014","journal-title":"Crit. Rev. Oncog."},{"issue":"5","key":"10.1016\/j.yexmp.2024.104898_bb0200","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00262-014-1523-1","article-title":"Interleukin 12: still a promising candidate for tumor immunotherapy?","volume":"63","author":"Lasek","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"issue":"5","key":"10.1016\/j.yexmp.2024.104898_bb0205","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1479-5876-5-66","article-title":"Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease < 1 cm) associated with ovarian cancer or primary peritoneal carcinoma","author":"Lenzi","year":"2007","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.yexmp.2024.104898_bb0210","first-page":"2541","article-title":"Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production","volume":"90","author":"Leonard","year":"1997","journal-title":"Blood"},{"issue":"41","key":"10.1016\/j.yexmp.2024.104898_bb0215","doi-asserted-by":"crossref","first-page":"30419","DOI":"10.1074\/jbc.M604868200","article-title":"Transcriptional regulation of ULBP1, a human ligand of the NKG2D receptor*","volume":"281","author":"L\u00f3pez-Soto","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.yexmp.2024.104898_bb0220","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.18632\/oncotarget.6567","article-title":"Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations","volume":"7","author":"Lorenz","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.yexmp.2024.104898_bb0225","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.bcp.2006.04.004","article-title":"3\u2032-Azido-3\u2032-deoxythymidine (AZT) is a competitive inhibitor of thymidine phosphorylation in isolated rat heart and liver mitochondria","volume":"72","author":"Lynx","year":"2006","journal-title":"Biochem. Pharmacol."},{"issue":"4","key":"10.1016\/j.yexmp.2024.104898_bb0230","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1084\/jem.177.4.1199","article-title":"Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells","volume":"177","author":"Manetti","year":"1993","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.yexmp.2024.104898_bb0235","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1089\/hgtb.2012.050","article-title":"Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells","volume":"23","author":"Marin","year":"2012","journal-title":"Hum. Gene Ther. Methods"},{"issue":"3","key":"10.1016\/j.yexmp.2024.104898_bb0240","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/1097-0142(196909)24:3<520::AID-CNCR2820240313>3.0.CO;2-M","article-title":"Cultivation in vitro of cells derived from a human rhabdomyosarcoma","volume":"24","author":"McAllister","year":"1969","journal-title":"Cancer"},{"key":"10.1016\/j.yexmp.2024.104898_bb0245","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-4939-8922-5_5","article-title":"Generation of suicide gene-modified chimeric antigen receptor-redirected T-cells for Cancer immunotherapy","volume":"1895","author":"Minagawa","year":"2019","journal-title":"Methods Mol. Biol."},{"issue":"4","key":"10.1016\/j.yexmp.2024.104898_bb0250","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1182\/blood.V89.4.1334","article-title":"Thymidine kinase (TK) gene-transduced human lymphocytes can be highly purified, remain fully functional, and are killed efficiently with ganciclovir","volume":"89","author":"Munshi","year":"1997","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.yexmp.2024.104898_bb0255","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/08923979209005399","article-title":"Immunological consequences of zidovudine treatment in control and morphine or methadone treated mice","volume":"14","author":"Pacifici","year":"1992","journal-title":"Immunopharmacol. Immunotoxicol."},{"issue":"1","key":"10.1016\/j.yexmp.2024.104898_bb0260","doi-asserted-by":"crossref","first-page":"8321","DOI":"10.1038\/s41598-021-87700-2","article-title":"Sarcoma IL-12 overexpression facilitates NK cell immunomodulation","volume":"11","author":"Rademacher","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.yexmp.2024.104898_bb0265","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1073\/pnas.0507496103","article-title":"Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells","volume":"103","author":"Recchia","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"10","key":"10.1016\/j.yexmp.2024.104898_bb0270","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0078711","article-title":"The engineered thymidylate kinase (TMPK)\/AZT enzyme-prodrug axis offers efficient bystander cell killing for suicide gene therapy of cancer","volume":"8","author":"Sato","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.yexmp.2024.104898_bb0275","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1158\/2159-8290.CD-17-1152","article-title":"Genome-informed targeted therapy for osteosarcoma","volume":"9","author":"Sayles","year":"2019","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.yexmp.2024.104898_bb0280","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/gt.2011.210","article-title":"Engineered human Tmpk fused with truncated cell-surface markers: versatile cell-fate control safety cassettes","volume":"20","author":"Scaife","year":"2013","journal-title":"Gene Ther."},{"issue":"7","key":"10.1016\/j.yexmp.2024.104898_bb0285","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2015.1014760","article-title":"Cancer-targeted IL-12 controls human rhabdomyosarcoma by senescence induction and myogenic differentiation","volume":"4","author":"Schilbach","year":"2015","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.yexmp.2024.104898_bb0290","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/978-1-0716-0203-4_8","article-title":"In vivo assessment of NK cell-mediated cytotoxicity by adoptively transferred Splenocyte rejection","volume":"2097","author":"Schloemer","year":"2020","journal-title":"Methods Mol. Biol."},{"issue":"12","key":"10.1016\/j.yexmp.2024.104898_bb0295","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30701","article-title":"Prognosis of children and young adults with newly diagnosed rhabdomyosarcoma metastatic to bone marrow treated on Children\u2019s oncology group studies","volume":"70","author":"Schloemer","year":"2023","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.yexmp.2024.104898_bb0300","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-030-43085-6_1","article-title":"Genomic complexity of osteosarcoma and its implication for preclinical and clinical targeted therapies","volume":"1258","author":"Schott","year":"2020","journal-title":"Adv. Exp. Med. Biol."},{"issue":"1","key":"10.1016\/j.yexmp.2024.104898_bb0305","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1089\/10430340460732463","article-title":"Characterization of CD20-transduced T lymphocytes as an alternative suicide gene therapy approach for the treatment of graft-versus-host disease","volume":"15","author":"Serafini","year":"2004","journal-title":"Hum. Gene Ther."},{"issue":"15","key":"10.1016\/j.yexmp.2024.104898_bb0310","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1200\/JCO.2009.27.0421","article-title":"Outcomes for children and adolescents with cancer: challenges for the twenty-first century","volume":"28","author":"Smith","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.yexmp.2024.104898_bb0315","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1089\/10430349950018030","article-title":"Characterization of genetically altered, interleukin 2-independent natural killer cell lines suitable for adoptive cellular immunotherapy","volume":"10","author":"Tam","year":"1999","journal-title":"Hum. Gene Ther."},{"issue":"11","key":"10.1016\/j.yexmp.2024.104898_bb0320","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.yexmp.2024.104898_bb0325","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood.V84.4.1333.1333","article-title":"Ganciclovir treatment of herpes simplex thymidine kinase-transduced primary T lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation?","volume":"84","author":"Tiberghien","year":"1994","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.yexmp.2024.104898_bb0330","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28072","article-title":"Omic approaches to pediatric bone sarcomas","volume":"67","author":"Tirtei","year":"2020","journal-title":"Pediatr. Blood Cancer"},{"issue":"2","key":"10.1016\/j.yexmp.2024.104898_bb0335","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nri1001","article-title":"Interleukin-12 and the regulation of innate resistance and adaptive immunity","volume":"3","author":"Trinchieri","year":"2003","journal-title":"Nat. Rev. Immunol."},{"issue":"5","key":"10.1016\/j.yexmp.2024.104898_bb0340","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.yexmp.2024.104898_bb0345","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27313","article-title":"Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens","volume":"65","author":"Wedekind","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"issue":"11","key":"10.1016\/j.yexmp.2024.104898_bb0350","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/jcmm.12121","article-title":"Localized interleukin-12 delivery for immunotherapy of solid tumours","volume":"17","author":"Wei","year":"2013","journal-title":"J. Cell. Mol. Med."},{"issue":"6","key":"10.1016\/j.yexmp.2024.104898_bb0355","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.3892\/or_00001026","article-title":"Sodium valproate, a histone deacetylase inhibitor, augments the expression of cell-surface NKG2D ligands, MICA\/B, without increasing their soluble forms to enhance susceptibility of human osteosarcoma cells to NK cell-mediated cytotoxicity","volume":"24","author":"Yamanegi","year":"2010","journal-title":"Oncol. Rep."},{"issue":"1","key":"10.1016\/j.yexmp.2024.104898_bb0360","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","article-title":"Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity","volume":"18","author":"Yu","year":"2019","journal-title":"Mol. Cancer"},{"issue":"10","key":"10.1016\/j.yexmp.2024.104898_bb0365","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1158\/1078-0432.CCR-14-2085","article-title":"Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma","volume":"21","author":"Zhang","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.yexmp.2024.104898_bb0370","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000210","article-title":"Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models","volume":"8","author":"Zhang","year":"2020","journal-title":"J. Immunother. Cancer"}],"container-title":["Experimental and Molecular Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480024000170?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014480024000170?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T00:46:44Z","timestamp":1718412404000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014480024000170"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":74,"alternative-id":["S0014480024000170"],"URL":"https:\/\/doi.org\/10.1016\/j.yexmp.2024.104898","relation":{},"ISSN":["0014-4800"],"issn-type":[{"value":"0014-4800","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fate control engagement augments NK cell responses in LV\/hu-IL-12 transduced sarcoma","name":"articletitle","label":"Article Title"},{"value":"Experimental and Molecular Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yexmp.2024.104898","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"104898"}}